PURPOSE: Alterations in the KEAP1/NFE2L2 (NRF2)/CUL3 pathway occur in ~20% of human head and neck squamous cell carcinomas (HNSCC) and are associated with resistance to standard-of-care therapy. However, this pathway's role in radiotherapy resistance in HNSCC has not been well-studied. EXPERIMENTAL DESIGN: We generated genetically engineered mouse models and developed primary murine cancer cell lines harboring mutations commonly observed in human HNSCC, including inducible activation of PIK3CA and deletion of Trp53, with or without Keap1 loss. Primary tumors were initiated via 4-hydroxytamoxifen injection ± the tobacco carcinogen benzo[a]pyrene (BAP) into the oral buccal mucosa. Tumors were analyzed using Western blotting, immunohistochemistry, RNA sequencing (RNA-seq), and subjected to fractionated radiation therapy to investigate the role of the KEAP1/NRF2 pathway in radioresistance and modulation of the tumor immune microenvironment. RESULTS: BAP exposure accelerated primary tumor formation within one month, with histological analysis confirming invasive squamous cell carcinoma, validated by cytokeratin and differentiation marker expression. Primary cell lines derived from Keap1-haploinsufficient tumors exhibited upregulation of NRF2 target genes and a radioresistant phenotype, which was reversed post-Nrf2 knockdown in vitro. Bulk RNA-seq revealed that Keap1 haploinsufficiency correlated with NRF2 pathway activation, increased myeloid infiltration, and enhanced angiogenic signatures. In vivo, Keap1 haploinsufficiency promoted accelerated tumor growth and decreased survival. Finally, using fractionated radiotherapy, we showed that Keap1 haploinsufficient primary tumors were significantly more radioresistant than Keap1-proficient tumors, regardless of BAP exposure. CONCLUSION: These data demonstrate that Keap1 haploinsufficiency in HNSCC is linked to unfavorable tumor immune microenvironment, aggressive growth, and a radioresistant phenotype.
Nrf2 hyperactivation as a driver of radiotherapy resistance and suppressed anti-tumor immunity in head and neck squamous cell carcinoma.
Nrf2 过度激活是头颈部鳞状细胞癌放射治疗耐药性和抗肿瘤免疫抑制的驱动因素
阅读:4
作者:Patel Rutulkumar, Saab Kalil, Luo Lixia, Ma Yan, Osman Rashid Abdullah, Williams Nerissa T, Everitt Jeffrey, Zelazowski Maciej J, Castro Patricia, Decker William K, Hudson William H, Myers Jeffrey N, Sandulache Vlad C, Frederick Mitchell J, Mowery Yvonne M, Kirsch David G
| 期刊: | Clinical Cancer Research | 影响因子: | 10.200 |
| 时间: | 2025 | 起止号: | 2025 Jul 31 |
| doi: | 10.1158/1078-0432.CCR-25-0112 | 研究方向: | 肿瘤 |
特别声明
1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。
2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。
3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。
4、投稿及合作请联系:info@biocloudy.com。
